L-leucine, an FDA-approved compound, exerts neuroprotective effects in Parkinson’s disease models. By reducing alpha-synuclein aggregation and restoring dopamine signaling, NALL targets multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results